T2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant Bacteria
"The ability to rapidly diagnose and treat drug-resistant bacteria will save lives by enabling doctors to treat patients more quickly and effectively than is possible with today's diagnostic tools," said
CARB-X's mission is to drive antibacterial innovation and combat the growing threat of antimicrobial resistance. It is jointly led by BARDA, a government agency at the U.S.
"The collaboration with CARB-X will accelerate the development of diagnostic tests to identify major bacterial species and resistance genes faster than ever," said
Rapid diagnosis means better and faster treatment with fewer deaths
Bacterial bloodstream infections can be deadly even at low concentrations. If bacterial infections are identified quickly, patients can be placed on effective antibiotic therapy faster. The
The new tests aim to address the most serious superbugs and resistance genes on the antibiotic-resistance threat list published by the
In addition to speeding diagnosis and treatment of patients, these tests could be used to accelerate clinical trials for new antibiotics and reduce their time to market.
T2 Biosystems Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding uptake or adoption of products, future aspects and anticipated benefits of the collaboration with CARB-X, additional patients, timing of testing patients, anticipated product benefits or access, strategic priorities, product expansion or opportunities, growth expectations or targets and timing or occurrence of FDA filings or clearances or commercial releases. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; (iv) reliance on third parties; (v) competitive factors; (vi) manufacturing or supply disruptions; (v) regulatory factors; (vi) risks related to intellectual property; or (vii) the factors discussed under Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission, or SEC, on March 15, 2017, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.
CARB-X is one of the world's largest public-private partnership devoted to early development antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines, rapid diagnostics and devices to treat drug-resistant bacterial infections. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI). http://www.carb-x.org/.
This press release is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust. The contents are solely the responsibility of the authors and do not necessarily represent the official views of CARB-X, the HHS Office of the Assistant Secretary for Preparedness and Response, the National Institutes of Health or Wellcome Trust.
CARB-X was created in response to the US government's 2015 National Action Plan for Combating Antibiotic Resistant Bacteria (CARB) and the UK government's call in 2016 for a concerted global effort to tackle antibiotic resistance. A non-profit partnership, it is headquartered at Boston University. CARB-X was launched by the US Department of Health and Human Services (HHS)'s Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID/NIH). Funders are BARDA and Wellcome Trust. NIAID provides preclinical services support. Other partners include the Broad Institute of MIT and Harvard, the Massachusetts Biotechnology Council (MassBio), the California Life Sciences Institute (CLSI), and RTI International. CARB-X projects are selected through a global competitive process. Applications are vetted by the CARB-X Science Advisory Board. To be considered, projects must target one of the antibiotic resistant bacteria on the Serious or Urgent Threat List prepared by the CDC or on the Priority Pathogens list published by the WHO.
T2 Biosystems Media Contact:
Amy Phillips, Feinstein Kean Healthcare
T2 Biosystems Investor Contact:
Chris Brinzey, Westwicke Partners
CARB-X Media Contact: